share_log

Pfizer | SC TO-C: Written communication relating to an issuer or third party tender offer

Pfizer | SC TO-C: Written communication relating to an issuer or third party tender offer

辉瑞 | SC TO-C:投标报价书面通信
美股sec公告 ·  07/30 17:22
Moomoo AI 已提取核心信息
Pfizer Inc. has announced a proposed modification offer for certain eligible participants holding Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. The modification aims to extend the terms of these awards by two years, effectively converting them into seven-year TSRUs. This initiative is designed to retain talent and align their interests with those of shareholders by providing value tied to Pfizer's stock performance. The offer is voluntary and requires action from participants who wish to accept it during the open window period from August 12 through September 12, 2024. Pfizer will file a Tender Offer Statement with the SEC, and the offer will be made only through the Modification Offer and related materials, which will be available on the Fidelity NetBenefits online portal, Pfizer's website, and the SEC's website. The company has communicated this proposal to the eligible participants and will hold information sessions on August 14, 2024, to discuss the program details.
Pfizer Inc. has announced a proposed modification offer for certain eligible participants holding Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023. The modification aims to extend the terms of these awards by two years, effectively converting them into seven-year TSRUs. This initiative is designed to retain talent and align their interests with those of shareholders by providing value tied to Pfizer's stock performance. The offer is voluntary and requires action from participants who wish to accept it during the open window period from August 12 through September 12, 2024. Pfizer will file a Tender Offer Statement with the SEC, and the offer will be made only through the Modification Offer and related materials, which will be available on the Fidelity NetBenefits online portal, Pfizer's website, and the SEC's website. The company has communicated this proposal to the eligible participants and will hold information sessions on August 14, 2024, to discuss the program details.
辉瑞公司已宣布为持有2022年和2023年授予的五年股东总回报计量单位(TSRUs)和业绩股奖励(PSAs)的一些合格参与者提出拟议的修改要约。此次修改的目标是将这些奖励的期限延长两年,有效地将它们转换为为期七年的TSRUs。该举措旨在通过提供与辉瑞股票业绩相关的价值,留住人才并将他们的利益与股东的利益保持一致。该要约是自愿的,并要求参与者在2024年8月12日至9月12日期间采取行动才能接受它。辉瑞将向SEC提交要约声明,而该要约将仅通过与修改要约和相关材料一起提供的Fidelity NetBenefits在线门户、辉瑞公司网站和SEC网站发布。公司已向合格参与者传达了该提议,并将于2024年8月14日举行信息会议,讨论该计划的详细内容。
辉瑞公司已宣布为持有2022年和2023年授予的五年股东总回报计量单位(TSRUs)和业绩股奖励(PSAs)的一些合格参与者提出拟议的修改要约。此次修改的目标是将这些奖励的期限延长两年,有效地将它们转换为为期七年的TSRUs。该举措旨在通过提供与辉瑞股票业绩相关的价值,留住人才并将他们的利益与股东的利益保持一致。该要约是自愿的,并要求参与者在2024年8月12日至9月12日期间采取行动才能接受它。辉瑞将向SEC提交要约声明,而该要约将仅通过与修改要约和相关材料一起提供的Fidelity NetBenefits在线门户、辉瑞公司网站和SEC网站发布。公司已向合格参与者传达了该提议,并将于2024年8月14日举行信息会议,讨论该计划的详细内容。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息